🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Anderson-Fabry Disease

Fabry Cardiomyopathy: Identification of Early Myocardial Structural and Tissue Abnormalities Using Multiparametric MRI NCT04856059NA1 site📍 Toronto University Health Network, Toronto · Tests: Cardiac MRI, ECG/Holter and Blood Biomarkers Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study NCT06758648n/a1 site📍 München Technical University of Munich · Tests: Dynamic retinal vessel analysis (DVA), Biochemistry and immune phenotyping, Questionnaires (Patient reported outcomes),… Evaluate the Safety and Preliminary Efficacy of EXG110 in Subjects With Fabry Disease NCT06539624NA2 sites📍 Shanghai📍 Hangzhou The Children's Hospital of Zhejiang University School of Me… · Tests: EXG110 injection Anderson-Fabry Disease Fitness Improvement Training NCT07495410NA1 site📍 Prague General University Hospital, Prague · Tests: Physiotherapy exercise programe Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease NCT05698901n/a1 site📍 Taipei Mackay Memorial Hospital · Tests: Agalsidase beta Precision Diagnosis and Risk Stratification of Rare Cardiomyopathies Based on Novel Cardiac Magnetic Resonance Techniques NCT07336394n/a1 site📍 Beijing Chinese Academy of Medical Sciences, Fuwai Hospital A Study of Patients With Fabry Disease (US Specific) NCT06906367n/a8 sites📍 Birmingham📍 Little Rock📍 Atlanta Amicus Therapeutics · Tests: migalastat HCl, ERT Characterization of Patients With Cardiomyopathy to Identify Critical Patients Candidates for Cardiac Transplantation NCT06813443n/a3 sites📍 Bologna📍 Roma📍 Florence IRCCS Azienda Ospedaliero-Universitaria di Bologna A Global Prospective Observational Study of Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding NCT04252066n/a1 site📍 Philadelphia Amicus Therapeutics · Tests: migalastat the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease NCT06776419n/a1 site📍 Copenhagen Caroline Michaela Kistorp · Tests: Cardiac Magnetic Ressonance Imaging, 82Rubidium-positron emission tomography and computer-tomography Natural History and Structural Functional Relationships in Fabry Renal Disease Treatment Outcomes(Changes)in Fabry Renal Disease Study NCT01581424n/a2 sites📍 Minneapolis📍 Minneapolis University of Minnesota 4D-310 in Adults With Fabry Disease and Cardiac Involvement NCT05629559Phase 1, Phase 24 sites📍 Melbourne📍 Perth📍 Westmead 4D Molecular Therapeutics · Tests: 4D-310 Canadian Fabry Disease Initiative (CFDI) National Registry NCT00455104n/a5 sites📍 Calgary📍 Vancouver📍 Halifax Canadian Fabry Research Consortium · Tests: No intervention A Study of Replagal in Children and Adults With Fabry Disease in India NCT05067868Phase 43 sites📍 Kolkata📍 New Delhi📍 New Delhi Shire · Tests: Replagal Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Disease NCT06270316Phase 1, Phase 210 sites📍 Birmingham📍 Los Angeles📍 Atlanta UniQure Biopharma B.V. · Tests: AMT-191 Italian Anderson Fabry Disease Cardiovascular Registry NCT06806813n/a54 sites📍 Chieti📍 Potenza📍 Caserta IRCCS Azienda Ospedaliero-Universitaria di Bologna Cardiovascular Multimodality Imaging Study NCT06610019n/a1 site📍 The Bronx Montefiore Medical Center A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry Disease NCT07187440n/a18 sites📍 Hefei📍 Beijing📍 Beijing Takeda · Tests: No intervention Study of the Quality of Life of Patients With Fabry Disease Aged 65 and Over With and Without Specific Treatment NCT07277361n/a1 site📍 Paris Wladimir MAUHIN, Dr A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease NCT06858397Phase 1, Phase 210 sites📍 Los Angeles📍 Kansas City📍 Minneapolis GC Biopharma Corp · Tests: HM15421/GC1134A Evaluation of the Safety, Tolerability and Efficacy of a Gene Therapy Drug for the Treatment of Pediatric Fabry Disease NCT06207552EARLY Phase 11 site📍 Shanghai Children's Hospital of Fudan University · Tests: BBM-F101 injection A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease NCT06328608Phase 2, Phase 312 sites📍 Phoenix📍 Atlanta📍 Iowa City Chiesi Farmaceutici S.p.A. · Tests: PRX-102 1 mg/kg every two weeks Myocardial Perfusion CMR for Differentiating and Characterizing Hypertrophic Cardiomyopathy Phenotypes NCT07382128n/a1 site📍 Bologna IRCCS Azienda Ospedaliero-Universitaria di Bologna Functional Capacity in Anderson-Fabry Disease Patients NCT06884358n/a5 sites📍 Brescia📍 Milan📍 San Donato Milanese IRCCS Policlinico S. Donato Observational Study on Long-term Use of Pegunigalsidase Alfa in Fabry Patients in a Real-world Setting NCT07109375n/a7 sites📍 Arezzo📍 Bari📍 Bologna Chiesi Italia · Tests: pegunigalsidase alfa Taiwan Associated Genetic and Nongenetic Small Vessel Disease NCT05473637n/a1 site📍 Taipei National Taiwan University Hospital · Tests: MRI Multimodal and Multidisciplinary Approach to Optimize Diagnostic, Prognostic, and Therapeutic Management of Patients with Non-ischemic Cardiomyopathies and Arrhythmogenic-inflammatory Phenotypes: a Multicenter, Observational, Retrospective and Prospective Registry Study. NCT06607471n/a1 site📍 Milan Scientific Institute San Raffaele · Tests: Support treatment, cardiac medical treatment, aetiology-specific treatment, device implant, arrhythmia ablation, Suppor… Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease NCT05710692Phase 2, Phase 310 sites📍 Chikushino-shi📍 Sendai📍 Nishihara Chiesi Farmaceutici S.p.A. · Tests: PRX-102 1 mg/kg every 2 weeks, PRX-102 2 mg/kg every 4 weeks Fabry Disease Registry & Pregnancy Sub-registry NCT00196742n/a284 sites📍 Birmingham📍 Birmingham📍 Phoenix Genzyme, a Sanofi Company Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease NCT06325488n/a1 site📍 Copenhagen Caroline Michaela Kistorp
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy